Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.05.23	Biogen : Canada Accepts New Drug Submission For Lecanemab As Treatment For Early Alzheimer's Disease (RTTNews)
16.05.23	Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease (GlobeNewswire)
26.04.23	FDA Grants Accelerated Approval For Biogen's ALS Drug (RTTNews)
25.04.23	FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS (GlobeNewswire)
25.04.23	Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook (RTTNews)
31.03.23	Biotech Stocks Facing FDA Decision In April 2023 (RTTNews)
31.03.23	Eisai, Biogen Present Lecanemab New Analyses In Phase 3 Trial; Detailed Analyses In Phase IIb Trial (RTTNews)
31.03.23	ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS (PR Newswire)
31.03.23	EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING (PR Newswire)
31.03.23	Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting (GlobeNewswire)
31.03.23	Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals (GlobeNewswire)
29.03.23	Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions (RTTNews)
29.03.23	New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease (GlobeNewswire)
23.03.23	Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS (RTTNews)
23.03.23	Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS (GlobeNewswire)
16.03.23	Biogen Gets Favorable EU Court Ruling For TECFIDERA Regulatory Data And Marketing Protection (RTTNews)
16.03.23	Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection (GlobeNewswire)
08.03.23	Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors (GlobeNewswire)
06.03.23	FDA Grants Priority Review For Approval Of Eisai's Leqembi For Alzheimer's Disease Treatment (RTTNews)
06.03.23	FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease (GlobeNewswire)
06.03.23	FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
28.02.23	Biotech Stocks Facing FDA Decision In March 2023 (RTTNews)
28.02.23	Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China (RTTNews)
28.02.23	BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION (PR Newswire)
28.02.23	Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration (GlobeNewswire)
15.02.23	Biogen Q4 Results Top Estimates (RTTNews)
15.02.23	Biogen Inc. Q4 Profit Increases, beats estimates (RTTNews)
06.02.23	Sage Therapeutics: FDA To Review NDA For Zuranolone - Quick Facts (RTTNews)
30.01.23	Eisai : Lecanemab Receives Priority Review Status In Japan For Alzheimer's Disease Treatment (RTTNews)
30.01.23	LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN (PR Newswire)
27.01.23	Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease (RTTNews)
27.01.23	MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY (PR Newswire)
16.01.23	EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN (PR Newswire)
11.01.23	Eisai Submits MAA For Lecanemab As Treatment For Early Alzheimer's Disease In Europe (RTTNews)
11.01.23	EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE (PR Newswire)
07.01.23	Eisai Submits SBLA To FDA For Traditional Approval Of Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	FDA Approves Eisai And Biogen's Leqembi For Alzheimer's Disease Treatment (RTTNews)
07.01.23	Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease (PR Newswire)
06.01.23	FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease (PR Newswire)
04.01.23	Biogen Announces License Agreement With Alcyone For ThecaFlex DRx System (RTTNews)
30.12.22	Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug (RTTNews)
23.12.22	EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA (PR Newswire)
19.12.22	Biogen Signs Agreement With Genentech For Royalties On Glofitamab (RTTNews)
09.12.22	Biogen : FDA Accepts BLA For BIIB800, Biosimilar Candidate Referencing ACTEMRA (RTTNews)
05.12.22	Biogen's Tofersen MAA Accepted In Europe To Treat Rare, Genetic Form Of ALS (RTTNews)
30.11.22	Eisai Clarifies Lecanemab Not Associated With Two Deaths In Alzheimer's Disease Treatment Trial (RTTNews)
30.11.22	EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE (PR Newswire)
30.11.22	ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGL... (PR Newswire)
29.11.22	Eisai, Biogen Hit By 2nd Death Related To Alzheimer Trial Drug (RTTNews)
21.11.22	Form 3 875045 (RSS)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende
19.11.24		Schwacher Handel: SDAX fällt nachmittags
19.11.24		Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste
19.11.24		Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer
19.11.24		Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende

19.11.24

Schwacher Handel: SDAX fällt nachmittags

19.11.24

Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste

19.11.24

Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer

19.11.24

Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Biogen Inc

Aktien Top/Flop

Biogen Peer Group Nachrichten

Meistgelesene Nachrichten